Medical Oncology

Urogenital Cancers

Urogenital Cancer Medical Oncologists in Melbourne

Urogenital cancers include malignancies affecting the urinary system and male reproductive organs, as well as selected adrenal cancers managed within this oncology stream. Northern Blood & Cancer Care provides specialist medical oncology care in Melbourne for adrenocortical cancer, bladder and other urothelial cancers, kidney (renal) cancer, testicular cancer and penile cancer. Prostate cancer is covered separately on our dedicated Prostate Cancer page.

Treatment varies substantially between these cancers.

Surgery may be the main treatment for localised disease, while medical oncology becomes particularly important when treatment is required before or after surgery, when cancer has spread, or when immunotherapy, chemotherapy, targeted medicines or other systemic treatments are being considered. Care is coordinated with urologists, surgeons, radiation oncologists, radiologists, pathologists and other specialists according to the diagnosis.

Conditions & Treatments

Adrenocortical cancer arises from the outer layer of the adrenal gland and is uncommon. Some tumours produce excess hormones, which can cause symptoms such as high blood pressure, weight changes, weakness or changes in hormone balance, while others are discovered because of pain or an incidental scan finding. Assessment generally combines dedicated imaging, hormone testing and specialist surgical review. Surgery is central for localised disease. Depending on stage and recurrence risk, medical treatment may include mitotane, chemotherapy or other systemic approaches, with complex cases often benefiting from discussion through a tertiary multidisciplinary service.
Urothelial cancer most commonly begins in the bladder but can also arise in the renal pelvis or ureter. Early bladder cancers are often managed by urologists with cystoscopy, transurethral resection and, in selected cases, treatment delivered directly into the bladder. Medical oncology has an important role in muscle-invasive, recurrent or metastatic disease. Treatment may include chemotherapy before surgery, immunotherapy, antibody-drug conjugates or biomarker-selected targeted therapy. Pathology, stage, kidney function, previous treatment and molecular findings all influence which systemic treatment is most appropriate.
Most kidney cancers are renal cell carcinomas, although several biological subtypes exist. Small localised tumours may be managed with surgery, ablation or surveillance depending on size, location and the patient’s health. Medical oncology is particularly involved when kidney cancer is high risk after surgery, cannot be removed completely or has spread to other organs. Modern systemic treatment commonly uses immunotherapy, targeted medicines that affect tumour signalling or blood-vessel growth, or combinations of these approaches. Treatment selection takes account of the cancer subtype, extent of disease, symptoms and other medical conditions.

Testicular cancer most often develops from germ cells and commonly affects younger men. It is divided broadly into seminoma and non-seminomatous germ-cell tumours, which differ in their behaviour and treatment. Assessment includes ultrasound, staging imaging and tumour markers such as AFP, beta-hCG and LDH. Surgery to remove the affected testicle is usually the first treatment and provides the definitive pathology. Depending on stage and risk, some patients need surveillance while others receive chemotherapy or, less commonly, radiotherapy. Fertility and sperm banking should be discussed before treatment when future fertility is important.

Penile cancer is uncommon and is most often a squamous cell carcinoma. Early disease may be treated with local surgery or other organ-preserving approaches, while more advanced cancers require careful assessment of regional lymph nodes and may need more extensive surgery, radiotherapy or systemic treatment. Medical oncology may be involved when chemotherapy or other drug treatment is required before surgery, for nodal disease, or when cancer is recurrent or metastatic. Because penile cancer is rare, multidisciplinary review and referral to a service with tumour-specific surgical expertise can be important.

How We Investigate & Plan Care

Investigation begins by confirming the exact site and tumour type. Imaging may include CT, MRI, PET or other specialised scans depending on the cancer. Tissue diagnosis is usually important before systemic treatment is started, although some tumours are treated surgically first when the imaging and clinical situation are sufficiently characteristic. Blood tests assess organ function and treatment fitness, while tumour markers or hormone studies are used when they are relevant to the specific cancer.

Molecular and biomarker testing increasingly influences treatment for advanced urogenital cancers. Examples include testing for actionable alterations in selected urothelial cancers and genomic features that may guide targeted or immune-based treatment. The medical oncologist integrates these results with stage, previous treatment, kidney and liver function, other illnesses and the patient’s priorities before recommending a treatment plan.

Treatment & Care

Treatment & Ongoing Care

Systemic treatment can include chemotherapy, immunotherapy, targeted medicines, antibody-drug conjugates or other cancer-specific therapies. The aim may be to reduce the chance of recurrence after local treatment, improve the effectiveness of surgery or radiotherapy, or control advanced disease and its symptoms. Treatment is monitored with blood tests, clinical review and imaging, with dose or schedule changes made when needed for safety.

Northern Blood & Cancer Care provides private medical oncology consultations at Northern Private Hospital in Epping and can coordinate day treatment through Northern Private Hospital or Northern Health when clinically appropriate. Where a rare cancer, complex operation, specialised radiotherapy, nuclear medicine treatment or clinical trial requires tertiary expertise, the treating oncologist can coordinate referral while remaining involved in the patient’s ongoing oncology care.

Before You Visit

Preparing for Your Appointment

If you are attending for a new consultation, please bring a current referral, medication list and any relevant pathology, imaging, operative or hospital reports. If you have had a biopsy or surgery, the pathology report is particularly useful. Please also bring details of previous cancer treatment and, where available, molecular or genetic test results. Your specialist will explain the diagnosis, whether additional staging or testing is required and the systemic treatment options that are relevant to your situation. You are welcome to bring a family member or support person.

Our Experts

Northern Blood & Cancer Care brings together Melbourne specialists with complementary clinical, hospital and research appointments. The clinicians most closely associated with this service include:

Medical Oncology Expertise

Specialist Medical Oncology for Urogenital Cancers

Urogenital cancers differ substantially in their biology and treatment, from highly curable testicular cancers to kidney and urothelial cancers increasingly treated with immunotherapy and targeted medicines. Northern Blood & Cancer Care provides tumour-specific medical oncology assessment, contemporary systemic treatment planning and coordination with urology, surgery, radiotherapy and tertiary services when required.

Northern Blood & Cancer Care

Specialist Blood & Cancer Care in Melbourne

Northern Blood & Cancer Care brings together a highly experienced team of haematologists, medical oncologists and specialist physicians, with consultations available at Northern Private Hospital in Epping.

Contact our team to arrange an appointment or discuss a referral.